Urologist Boorjian Joins Fox Chase Cancer Center's Surgical Oncology Staff
PHILADELPHIA (August 5, 2008)—Fox Chase Cancer Center’s surgical oncology department has added Stephen A. Boorjian, MD, of Blue Bell, PA, to its urologic oncology staff. He treats patients with prostate, bladder, kidney, testicular, ureteral, penile and urethral cancers.
Boorjian has extensive training in minimally invasive surgery, including nerve-sparing surgery for men with prostate cancer. He also has specialty training in treatment for advanced cancers, such as kidney cancer with a blood vessel growth of the tumor (tumor thrombus), bladder cancer requiring construction of a new bladder (neobladder reconstruction) and surgery after chemotherapy for testicular cancer.
“Caring for patients with genitourinary cancers often involves a team approach,” Boorjian said. “I work closely with my colleagues in medical and radiation oncology to develop the most appropriate and effective individual treatment plan—one that provides the best chance for a cure while maintaining quality of life.”
Boorjian is the author of more than 50 professional journal papers and textbook chapters. He has made numerous presentations at meetings of the American Urological Association, the Society of Urologic Oncology and other professional organizations.
“I believe that active participation in research helps me to remain aware of the most current treatments available for my patients,” said Boorjian. His research interests include understanding the biological mechanisms underlying bladder and prostate cancer in order to develop novel treatments.
Boorjian received his medical degree at Harvard Medical School after earning his undergraduate degree with honors at Duke University. He interned and served residencies in surgery and urology at New York Presbyterian Hospital-Weill-Cornell Medical Center in New York City. He then completed a fellowship in urologic oncology at the Mayo Clinic in Rochester, MN.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.